Trodelvy

Active Ingredient(s): Sacituzumab Govitecan-hziy
FDA Approved: * April 22, 2020
Pharm Company: * IMMUNOMEDICS INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Trodelvy Overview

Sacituzumab govitecan, sold under the brand name Trodelvy, is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer.[1][2][3][4] The most common side effects are nausea, neutropenia, diarrhea, fatigue, anemia, vomiting, alopecia (hair loss), constipation, decreased appetite, rash and abdominal pain.[3 ...

Read more Trodelvy Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Sacituzumab_govitecan

Recent Trodelvy Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Sacituzumab Govitecan-hziy
  • Injection: 180mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Trodelvy: (1 result)

Sorted by National Drug Code
  • 55135-132 Trodelvy 180 mg Intravenous Powder, for Solution by Immunomedics, Inc.

Other drugs which contain Sacituzumab Govitecan-hziy or a similar ingredient: (1 result)